tranexamic acid oral / Generic mfg. - LARVOL DELTA

Evaluating Trauma Care Capacity and Capability in Low-Resource Conflict Settings: Pilot Implementation of the International Assessment of Capacity for Trauma-Blast Tool at Regional Health Facilities in Burkina Faso. (PubMed, World J Surg) - "The INTACT-B tool provides a feasible instrument for evaluating trauma care capacity and capability in LRCS. Significant needs both with respect to material resources, infrastructure, and training were identified in the study setting. Information generated through use of the INTACT-B tool may help guide efforts to strengthen regional and district health facilities closer to point-of-injury, which holds potential to reduce preventable death among local casualties in LRCS."

Journal

Triple-drug therapy with Goreisan, tranexamic acid and carbazochrome sodium sulfonate hydrate to prevent recurrence after chronic subdural haematoma surgery: a multicentre, randomised, controlled trial protocol. (PubMed, BMJ Open) - "A summary of the results will also be provided to participating institutions and made publicly available in accordance with the BMJ Open data sharing policy. jRCTs031240007."

Clinical protocol • Journal • Geriatric Disorders

Silent hemorrhage: Unraveling the insidious rectal bleeding in hermansky-pudlak syndrome (ASH 2025) - "Anti-fibrinolytics, such as aminocaproic acid and tranexamic acid, can decrease bleeding. Perioperatively, HPS patients should receive desmopressin acetate (DDAVP), but responsiveness testing should be conducted prior, as not all affected respond...Screening patients with hypopigmentation and bleeding disorders may be beneficial and appropriate. Identification would assist in prognosis as well as prophylaxis against severe bleeding."

Dyslipidemia • Endocrine Disorders • Gastroenterology • Gastrointestinal Disorder • Gynecology • Hematological Disorders • Hemophilia • Immunology • Metabolic Disorders • Rare Diseases • Thrombosis

A hospital policy of tranexamic acid to reduce transfusion in major non-cardiac surgery: The traction trial (ASH 2025) - P4 | "TRACTION ClinicalTrials.gov number, NCT04803747. Keywords: Clinical Trials, Research, Clinical Research"

Clinical • Late-breaking abstract • Surgery • Cardiovascular • Gynecology • Hematological Disorders • Myocardial Infarction • Orthopedics • Respiratory Diseases • Urology • Venous Thromboembolism

Use of emicizumab in patients with acquired hemophilia A: An interim safety analysis of a large-scale post‑marketing surveillance study (ASH 2025) - "A causal relationship with emicizumab was ruled out in all deaths.During emicizumab treatment, 21/51 (41.2%) patients used rFVIIa, 9/51 (17.6%) had transfusions, and7/51 (13.7%) received other hemostatic agents (FXIII, tranexamic acid). In this large-scale post-marketing study, emicizumab demonstrated a favorable safetyprofile in real-world clinical practice. While the study was not specifically designed to evaluate efficacy,the consistently low incidence of bleeding events observed supports the potential role of emicizumab ineffectively preventing bleeds in patients with AHA, reinforcing its positive risk–benefit profile at thisinterim analysis."

Clinical • P4 data • Biliary Cancer • Cholangiocarcinoma • CNS Disorders • Gastroenterology • Hemophilia • Hemophilia A • Immunology • Infectious Disease • Interstitial Lung Disease • Ischemic stroke • Lung Cancer • Nephrology • Peptic Ulcer • Pulmonary Disease • Rare Diseases • Respiratory Diseases • Solid Tumor

Real world evidence of treatment patterns in hereditary hemorrhagic telangiectasia (ASH 2025) - "Treatment examinedincluded bevacizumab, pazopanib, pomalidomide, aminocaproate, tranexamic acid (TXA), octreotide,lanreotide, thalidomide, tacrolimus, sirolimus, tamoxifen and raloxifene...The majority of HHT patients were treated withferrous sulfate (n=910), followed by iron sucrose, ferrous gluconate, ferric carboxymaltose, iron dextran,and ferric derisomaltose...While 8% of patients treated with TXA had VTE, the data does not support a definitiveconclusion of increased VTE in patients treated with anti-fibrinolytics. To further elucidate treatmentpractices in HHT, a multi-center approach incorporating review of medical records would providevaluable insights into real-world practices."

Clinical • HEOR • Real-world • Real-world evidence • Anemia • Aplastic Anemia • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Gastrointestinal Disorder • Hematological Disorders • Hypertension • Renal Disease • Venous Thromboembolism

A 10-year retrospective review of the effectiveness and safety of tranexamic acid in women with inherited bleeding disorders in the peripartum setting (ASH 2025) - "31% patients also received an additional hemostatic agent (17% received DDAVP, 15% receivedfactor concentrate -VWF:FVIII, FXI, FVIII, rFVIIa and FIX). This data suggests that TXA is associated with very low risk of thrombosis when used asprophylactic treatment for PPH among patients with inherited bleeding disorders in the puerperium.Under 1% of patients over 10 years experienced a thrombotic event and had two or more risk factors forVTE. In contrast, at least 17% had PPH despite provision of preventative peripartum hemostatic therapythat almost always included TXA. This suggests that on balance, TXA should be provided to patients withinherited bleeding disorders with the goal of PPH prevention but caution should be used in those with 2or more risk factors for thrombosis."

Retrospective data • Review • Cardiovascular • Hematological Disorders • Hemophilia • Hemophilia A • Hemophilia B • Obesity • Postpartum Hemorrhage • Pulmonary Embolism • Rare Diseases • Respiratory Diseases • Varicose Veins

Efficacy and safety of tranexamic acid in non-haemophilia bleeding disorders: A systematic review of randomized controlled trials (ASH 2025) - "TXA exhibits encouraging but preliminary evidence of safety and effectiveness in non hemophilicbleeding disorders. TXA is well tolerated and considerably lowers menstrual blood loss in patientswith vWF. Its usefulness in managing epistaxis in patients with hereditary hemorrhagictelangiectasia, however, seems to be limited."

Clinical • Review • Cardiovascular • Gastrointestinal Disorder • Hematological Disorders • Hemophilia • Mood Disorders • Rare Diseases

Peripartum FXI replacement supports safe neuraxial anesthesia in FXI-deficient parturients (ASH 2025) - "Data collection included age, ethnicity, parity, deliverymode, type of anesthesia (NA or general anesthesia (GA), estimated blood loss, use of hemostatic agents(e.g., FXI concentrate, Fresh frozen plasma (FFP), Tranexamic acid (TXA), Red blood cells (RBC), and FXIlevels (baseline and post-treatment if available)...Of the 22 vaginal deliveries, 21 (95.4%) received NA, andone received remifentanil patient-controlled analgesia (PCA) due to personal choice...Our PPH ratewas 14%, within the previously reported 11–22% range, and did not correlate with FXI levels. No PPHoccurred in patients receiving FXI concentrate."

Anesthesia • Cardiovascular • Hematological Disorders • Hemophilia • Obstetrics • Postpartum Hemorrhage

Hepatic plasminogen lowering with a galnac-conjugated siRNA reduces plasmin generation and fibrinolysis but has no effect on thrombin generation in rats and mice (ASH 2025) - P1/2 | "Introduction: Plasminogen (PLG) is primarily liver-derived and plays a key role in fibrinolysis.Antifibrinolytics, such as tranexamic acid, have been used clinically for decades to prevent bleeding byinhibiting the activation of PLG into plasmin, thereby reducing plasmin generation and fibrinolysis.Lowering hepatic PLG with an N-acetylgalactosamine (GalNAc)-conjugated small interfering RNA(PLG-lowering siRNA) is designed to reduce plasmin generation and fibrinolysis but to leave thrombingeneration unchanged. Hepatic PLG lowering with a GalNAc-conjugated siRNA reduced plasmin generation andplasma and whole blood fibrinolysis in rats, but had no effect on thrombin generation in rats and mice.These results suggest that targeting the fibrinolytic pathway with a liver-directed PLG-lowering siRNA willlikely not be associated with thrombotic risk and may be a safer option compared to alternatives thatincrease thrombin generation. The results support clinical development..."

Preclinical • Cardiovascular • Hematological Disorders • TINCR

Targeting hyperfibrinolysis: A novel prevention and reversal strategy. (ASH 2025) - "For example, the lysineanalog tranexamic acid (TXA), the most widely used antifibrinolytic agent, inhibits only one step in themulti-step fibrinolytic cascade...Noadverse effects related to ClearPlasma use were observed.Lastly, safety and efficacy were examined in humans comparing ClearPlasma with Fresh Frozen Plasma(FFP) in a prospective, multi-center, international, double-blind, randomized, two-arm, controlled clinicaltrial in patients undergoing Coronary Artery Bypass Grafting (CABG) or Valve Replacement withcardiopulmonary bypass that required transfusion of plasma.A total of 136 patients including 27 screening failures were enrolled, randomly divided in tow groups,ClearPlasma (n = 54) and FFP (n = 55) that were under follow-up for 30 days after the intervention.Patients given ClearPlasma required significantly fewer units of plasma than control group (p=0.0206)and in contrast to the controls, no significant drop in α2-antiplasmin concertation was recorded. Therewas..."

Anesthesia • Hematological Disorders • Thrombosis

A retrospective analysis of the safety and effectiveness of recombinant von willebrand factor in children with von willebrand disease undergoing surgery (ASH 2025) - P3 | "There were no reports of perioperative FVIII,tranexamic acid, desmopressin, anemia treatment, or need for transfusion. Results from this study suggest that off-label use of rVWF is effective for the perioperativemanagement of surgical bleeding in pediatric individuals with VWD undergoing major and minorprocedures, including those with severe disease. Results from this study suggest that off-label use of rVWF is effective for the perioperativemanagement of surgical bleeding in pediatric individuals with VWD undergoing major and minorprocedures, including those with severe disease. No new safety events were observed. These results lendfurther support for the positive benefit-risk profile for rVWF in a pediatric population."

Retrospective data • Surgery • Cardiovascular • Hematological Disorders • Hemophilia • Immunology • Rare Diseases • Thrombosis

Blood group o and a lower endogenous thrombin potential are associated with increased risk for future bleeding after hemostatic challenges in bleeding disorder of unknown cause (ASH 2025) - "In thisstudy, we investigated the association between prolonged bleeding or bleeding-related complicationsafter surgery or dental extractions and relevant coagulation-related laboratory parameters (hemoglobin,platelet count, fibrinogen, von Willebrand factor antigen and activity, C-reactive protein, thrombin andplasmin generation assays (all parameters) and native rotational thromboelastometry (clotting time, clotformation time, mean clot firmness, maximum lysis and area under the curve, AUC), measured at studyinclusion, by calculating univariate logistic regression models adjusted for age, sex, blood group O andthe use of bleeding prophylaxis, such as desmopressin or tranexamic acid.Results. Importantly, we couldshow an association between the endogenous thrombin generation potential, measured using acommercially available thrombin generation assay, and bleeding after hemostatic challenges in patientsafter the BDUC diagnosis. Lastly, our data highlights the importance..."

Hematological Disorders • CRP

BG09 Acquired haemophilia A in mucous membrane pemphigoid: beware of spontaneous bleeding in immunobullous diseases. (PubMed, Br J Dermatol) - "MMP was suspected, and treatment was initiated with prednisolone (10 mg once daily), doxycycline (200 mg once daily) and dapsone (50 mg once daily)...Prednisolone was increased to 20 mg once daily and dapsone was replaced with mycophenolate mofetil (MMF) 1 g twice daily, but there was no significant improvement...Prednisolone was increased to 50 mg once daily, MMF was continued and tranexamic acid was added to support clotting...A number of dermatological conditions have been associated with AHA, including immunobullous and autoimmune diseases. Screening for AHA should be undertaken in dermatology patients with autoimmune diagnoses who develop spontaneous or unusual bleeding."

Journal • Dermatology • Hematological Disorders • Hemophilia • Hemophilia A • Immunology • Rare Diseases • Respiratory Diseases

BC03 (P036) Is combining oral tranexamic acid and laser more effective in the management of melasma? A systematic review of efficacy and safety. (PubMed, Br J Dermatol) - "This comprehensive review highlights the benefits of adjunctive oral TXA in laser therapy for melasma, supporting its role as a valuable addition to current treatment regimens. More studies are warranted to further assess the effectiveness of combination treatments and explore long-term outcomes."

Journal • Review • Cardiovascular • Dermatology • Dermatopathology

P036 Is combining oral tranexamic acid and laser more effective in the management of melasma? A systematic review of efficacy and safety. (PubMed, Br J Dermatol) - "This comprehensive review highlights the benefits of adjunctive oral TXA in laser therapy for melasma, supporting its role as a valuable addition to current treatment regimens. More studies are warranted to further assess the effectiveness of combination treatments and explore long-term outcomes."

Journal • Review • Cardiovascular • Dermatology • Dermatopathology

Erratum: Author Correction: A comparative study of the local effect of tranexamic acid and phenylephrine on the amount of bleeding in rhinoplasty: A randomized clinical trial. (PubMed, Caspian J Intern Med) - "[This corrects the article on p. 690 in vol. 15, PMID: 39359446.]."

Clinical • Aesthetic Medicine

Trends in the Administration of Tranexamic Acid for Postpartum Hemorrhage (clinicaltrials.gov) - P=N/A | N=648 | Not yet recruiting | Sponsor: Mahidol University

New trial • Hematological Disorders • Postpartum Hemorrhage

Ethosome (ETHOSOMEPTT) Photothermal Therapy with Nd:YAG Laser (Pastelle Pro): A Novel Nanotechnology Approach for Treatment-resistant Melasma. (PubMed, Plast Reconstr Surg Glob Open) - "A clinical example demonstrates its utility: a 42-year-old woman with persistent malar melasma spanning 6 years, who had undergone treatment with hydroquinone, oral tranexamic acid, and neodymium-doped yttrium aluminum garnet laser with insufficient improvement, demonstrated a 68% reduction in Modified Melasma Area and Severity Index after 12 treatment sessions. The mechanism underlying ethosome photothermal therapy encompasses ethanol-mediated enhancement of stratum corneum permeability, targeted delivery via plasmonic nanoparticles, and controlled thermal effects on tissue structure. This methodology represents a potential advancement in melasma management, particularly for cases demonstrating limited response to conventional therapies."

Journal • Dermatology • Dermatopathology

Impact of tranexamic acid on hidden blood loss in intertrochanteric fractures: a meta-analysis of randomized controlled trials. (PubMed, Front Surg) - "Additionally, no significant difference in thromboembolic events was found between the two groups. Current evidence indicates that TXA significantly reduces HBL and transfusion requirements without increasing the risk of thromboembolic events in elderly patients with IFs."

Journal • Retrospective data • Review • Cardiovascular • Musculoskeletal Diseases • Orthopedics

The current status and future perspectives of transfusion products in Japan. (PubMed, J Anesth) - "The new 2025 Guideline for the Management of Critical Bleeding introduced recommendations on cryoprecipitate and fibrinogen use, and added guidance on tranexamic acid, calcium supplementation, and sodium bicarbonate. To reduce transfusion in routine clinical practice, autologous transfusion should also be considered. In 2024, the Blood Donation Promotion Committee emphasized the importance of research to develop new products."

Journal • Review • Hematological Disorders

Tranexamic acid for prevention of bleeding complications-a rational approach? : Results of a systematic literature review and evidence synthesis (PubMed, Urologie) - "In otherwise healthy patient populations, TXA appears to be a safe and effective means of preventing bleeding complications. Further studies are warranted in patients with cardiovascular risk factors before its unrestricted use can be recommended."

Journal • Cardiovascular • Renal Calculi

Global consensus on the management of melanin hyperpigmentation disorders. (PubMed, J Eur Acad Dermatol Venereol) - "Treatment options ranged from topical lightening agents and systemic therapies (e.g. oral tranexamic acid) to procedural interventions (e.g. chemical peels, lasers and IPL) stratified by disease subtype and pigmentation depth. Notably, the consensus highlights that effective MHD management must address not only melanocytes but also the surrounding skin microenvironment, including fibroblasts, mast cells and vascular components. This consensus provides a globally adaptable clinical guide for the diagnosis and management of MHD, emphasizing a personalized approach that bridges scientific rigour with real-world applicability across diverse populations and health systems."

Journal • Aesthetic Medicine • CNS Disorders • Depression • Dermatology • Dermatopathology • Mood Disorders • Psychiatry

Efficacy and Safety of Tranexamic Acid in Adult Liver Transplantation---ESTA Trial (clinicaltrials.gov) - P=N/A | N=1546 | Recruiting | Sponsor: RenJi Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatology • Transplantation

Impact of Tranexamic Acid in Breast Plastic Surgery: A Systematic Review and Meta-Analysis. (PubMed, Aesthetic Plast Surg) - "The evidence from this study suggests that perioperative TXA administration significantly reduces the risk of complications in plastic breast surgery and shortens hospital stays, improving patient outcomes and resource utilization. Notably, the risk of thromboembolic events remains unchanged, validating TXA's safety and underscoring its value in standard perioperative protocols for plastic breast surgery procedures."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Infectious Disease